In_the_dark_yet_again
07 Feb 2019
Kapoor to leave by end of 2019 I don’t see it either. It was just a bit of info about which I was unaware so was just sharing it in case anyone else is interested. I think far too much bad news is already priced in to the RB share price and, when things turn out to be not as bad as some have suggested, there’ll be a significant rally. I know the past is no guarantee of future but for many years up until early 2017 the RB share price was pretty solid at 2x the ULVR SP . Now I know the Mead Johnson acquisition was/is a bit of a pigs ear, not because it’s a bad business, more they just paid way too much, so it probably won’t get back to that kind of level for many years, if at all, but £60 RB vs £40 ULVR? That makes RB way too cheap relatively. The safe money will probably be with ULVR despite their recent results being spectacularly dull and underwhelming (which I don’t see changing much in the foreseeable future) which RB has much more upside IMO despite the numerous banana skins they will have to negotiate. Regards, ITDYA
Uncle_Doug
07 Feb 2019
Kapoor to leave by end of 2019 In_the_dark_yet_again: target price of £50 on the shares Good luck with that!!! How many years since it was this low? RB currently @5917 and one of the day’s biggest risers.
In_the_dark_yet_again
07 Feb 2019
Kapoor to leave by end of 2019 LSE:RB Found this comment on Citywire today. "Reckitt Benckiser catches cold, says Jefferies A weak cold and flu season in the US has impacted sales of Reckitt Benckiser’s (RB) biggest over-the-counter medicine Mucinex, which isn’t helpful to full-year figures, says Jefferies. Analyst Martin Deboo retained his ‘underperform’ rating and target price of £50 on the shares, which fell 1.7% to £58.57 yesterday. He said there was ‘acute downward pressure on Mucinex’, which accounts for 5% of group sales and more of profits. ‘We expect this to inhibit full-year 2019 guidance confidence ahead of the crunch prelims meeting on 18 February,’ he said. I don’t usually pay much attention to analysts but it is information(?) I didn’t know. Me, I think that, even if there is bad news in the pipeline, the current SP already reflects it. No more bad news is what I’m looking forward to! Regards, ITDYA Link is below. Not sure but yon may need a sign-in to read. [link]
newtonukequities
25 Jan 2019
Kapoor to leave by end of 2019 I’ve always liked this company and the current price is very tempting. Is the retirement of Rakesh Kapoor going to change RB at all? Warren Buffett always said that if its a great company then anyone can be in charge.
In_the_dark_yet_again
24 Jan 2019
Kapoor to leave by end of 2019 LSE:RB I just got a few more @5599 - given I’ve just bought it’s bound to go south as me buying is an almost perfect sell signal (at least in the short term!) Regards, ITDYA, not with an abundance of faith, just feeling this has sold off too far.
Uncle_Doug
24 Jan 2019
Kapoor to leave by end of 2019 Got a few more today @5650. Screaming buy.
Uncle_Doug
23 Jan 2019
Kapoor to leave by end of 2019 Getting close to 5800 Bill - time to buy - you know it makes sense! At some time in 2019 they’ll be back above 6400. Grab yourself an easy 10%.
NewBill1703
20 Jan 2019
Kapoor to leave by end of 2019 As discussed on here a few times in times past, ultimately he is carrying the can for the Mead Johnson deal - which will struggle to justify its price tag for a long time to come - and the consequent inability to do the deal with Pfizer for the Consumer Health business. Which would have made much more sense for RB…
Hydrogen_Economy
16 Jan 2019
Kapoor to leave by end of 2019 No RAKESH KAPOOR TO RETIRE AS CEO BY END OF 2019 Slough, UK January 16th 2019 - The Board of Reckitt Benckiser Group PLC today announced that Rakesh Kapoor has indicated his intention to retire as CEO by the end of 2019, after more than 8 years as CEO and 32 years at the company. RB’s Board has now initiated a formal process to appoint his successor, considering both internal and external candidates. Chris Sinclair, Chairman of the Board, said: “Under Rakesh’s leadership, RB has been transformed from a household cleaning business to a world leader in consumer health and hygiene. Rakesh has been both the visionary and the architect behind this strategic portfolio transformation since the mid-2000s. He has also developed RB2.0 - an organisation designed for sustainable growth and outperformance. On behalf of the Board, I want to express our appreciation for his vision, passion and leadership over his long and distinguished tenure. We are now commencing a formal and comprehensive process to appoint a successor, considering both internal and external candidates.†Rakesh Kapoor, Group Chief Executive Officer, said: “It has been a huge privilege to lead RB and I am very proud of the hard work and commitment of our people in delivering our success and many achievements. The last two years in particular, have been transformational with the acquisition of Mead Johnson, the catalyst for the creation of our two business units, Health and Hygiene, Home. 2020 will herald a new decade and I believe now is a good time for new leadership to take this great company through the next phase of outperformance. I will remain fully focussed on driving the business until a successor is in place.â€
Gamesinvestor1
01 Oct 2018
Top 10 Fundsmith September As of the 1st October report, RB has moved from number 9 to number 5 in one month. This can’t be purely due to the share price increase, he must have continued to add to the position in September methinks! TOP 10 HOLDINGS Amadeus Microsoft Paypal Idexx Reckitt Benckiser Facebook Philip Morris Waters Becton Dickinson Stryker Games
Gamesinvestor1
28 Sep 2018
Switch Looks like everyone is selling Unilever and buying RB, Ulvr down 0.6% - RB up 2.12% Games
Gamesinvestor1
07 Sep 2018
Top 10 Fundsmith Me too, although still low for me at 1.35% of my wad, I recently doubled my holding here. Games
Hydrogen_Economy
07 Sep 2018
Top 10 Fundsmith Games Well spotted, good post (increasingly rare on ii BBs). I added some RB in July so happy if Terry added at a slightly higher price. The RB. dip is unsurprising given the problems in key EM markets especially China but Indonesia and other currency devaluations will hit profit translations and market weakness will not help if EM consumers move down-market. MJ should be fairly resilient given the distrust of local baby formula after the melamine scandal. I’m sure Terry is looking beyond the short term ripples and sees the growth potential. As a holder of RB and Fundsmith, I hope he is right. H2
Gamesinvestor1
06 Sep 2018
Top 10 Fundsmith PORTFOLIO COMMENT FOR AUGUST 2018 There were no outright sales or purchases of holdings made in the month. The top 5 contributors in the month were Paypal, Amadeus, Microsoft, Idexx and Intuit. The top 5 detractors were Intertek, Philip Morris, Reckitt Benckiser, Sage and Diageo. My Comments >""""Interesting that Reckitt Benckinser has now moved into his top ten holdings for the first time in years. This implies he has bought a lot of the company in August, given that the share price is still on the lower end of it’s range. I may add to my holding here, as the Mead Johnson acquisition, whilst initially received poorly, was in line in the last quaterly results and the company recorded growth and increased the dividend by 6%. Debt is an issue, but the free cash flow is high, therefore debt reduction over time is likely. RB has increased it’s dividend by an average of over 11% for years. Also the share price has fallen quite a clip since Terry’s renewed investment, given that it traded between 67xx and 68xx during all of August and is now dowmto 6468. If Terry has his strategy right, then one can gain a few % on his August entry “â€""""" TOP 10 HOLDINGS Amadeus Paypal Microsoft Idexx Facebook Becton Dickinson Philip Morris Novo Nordisk Reckitt Benckiser Waters
picstIoup
27 Jul 2018
9% jump Has been a bumpy year or so but seems back on track again. Reclaiming £80 again would be good.
